Anthera Pharmaceuticals, Inc.
ANTH
ANTH was delisted on the 27th of June, 2018.
28 hedge funds and large institutions have $621K invested in Anthera Pharmaceuticals, Inc. in 2018 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 16 closing their positions.
3,129% more call options, than puts
Call options by funds: $452K | Put options by funds: $14K
33% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 6
24% less funds holding
Funds holding: 37 → 28 (-9)
56% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 16
90% less capital invested
Capital invested by funds: $6.37M → $621K (-$5.74M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$619K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$609K |
| 3 |
VF
Virtu Financial
New York
|
+$218K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$205K |
| 5 |
Goldman Sachs
New York
|
+$173K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$2.01M |
| 2 |
AC
Armistice Capital
New York
|
-$1.27M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.17M |
| 4 |
6CM
683 Capital Management
New York
|
-$399K |
| 5 |
Millennium Management
New York
|
-$111K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
6CM
26
683 Capital Management
New York
| – | -$399K | -276,809 | Closed |
|
|
27
Millennium Management
New York
| – | -$111K | -67,339 | Closed |
|
|
ARTA
28
A.R.T. Advisors
New York
| – | -$58K | -35,300 | Closed |
|
29
Neuberger Berman Group
New York
| – | -$56K | -34,110 | Closed |
|
30
D.E. Shaw & Co
New York
| – | -$41K | -24,606 | Closed |
|
|
OAM
31
Oxford Asset Management
Oxford,
United Kingdom
| – | -$32K | -20,133 | Closed |
|
|
BC
32
Birchview Capital
Burlington,
Vermont
| – | -$23K | -15,378 | Closed |
|
|
DADC
33
D.A. Davidson & Co
Great Falls,
Montana
| – | -$23K | -13,958 | Closed |
|
34
Wells Fargo
San Francisco,
California
| – | -$12.7K | -8,500 | -99% |
|
35
Macquarie Group
Sydney, NSW 2000,
Australia
| – | -$9K | -5,500 | Closed |
|
|
CHP
36
Cable Hill Partners
Portland,
Oregon
| – | -$1K | -500 | Closed |
|
|
FMA
37
FNY Managed Accounts
New York
| – | -$747 | -500 | Closed |
|
|
CG
38
Cutler Group
San Francisco,
California
| – | +$149 | +100 | New |
|
39
Barclays
London,
United Kingdom
| – | +$152 | +102 | +3,400% |
|
ANTH Hedge Fund Activity: Q1 2018 in Review
28 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Anthera Pharmaceuticals, Inc. (ANTH) for Q1 2018, worth a combined $621K — down 90% from $6.37M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of ANTH and 7 opened new positions — a net loss of 9 holders — while 6 trimmed existing stakes and 8 added.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $619K. The largest seller was BVF Inc, exiting entirely with an estimated $2.01M sold.
- 28 institutional investors held Anthera Pharmaceuticals, Inc. (ANTH) as of Q1 2018, down from 37 in Q4 2017.
- Funds reported $621K of Anthera Pharmaceuticals, Inc. stock for Q1 2018, down 90% quarter-over-quarter.
- 7 funds opened new Anthera Pharmaceuticals, Inc. positions in Q1 2018 and 16 closed out, a net change of -9 holders.
- The largest Anthera Pharmaceuticals, Inc. buyer in Q1 2018 was Renaissance Technologies, an estimated $619K added.
- The largest Anthera Pharmaceuticals, Inc. seller in Q1 2018 was BVF Inc, an estimated $2.01M sold.
Based on aggregated 13F filings for Q1 2018.